Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154
Rhea-AI Summary
Lipocine (Nasdaq:LPCN) will host a virtual KOL webinar on June 12, 2026 at 11:00 AM ET to highlight unmet needs in postpartum depression (PPD) and the clinical profile of LPCN 1154 (BRLIZIO™), its investigational oral brexanolone.
The event features expert presentations, Phase 3 topline data review, and a Q&A session.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – LPCN
On the day this news was published, LPCN gained 0.91%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
LPCN was down 2.67% while momentum-screened peers like PULM and NXTC were up 6.98% and 3.49%, respectively, suggesting today’s pressure was stock-specific rather than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 19 | Data presentation selection | Positive | -1.7% | Phase 3 LPCN 1154 data accepted for oral and poster presentations. |
| May 18 | Investor conference appearance | Neutral | -2.2% | Announcement of management fireside chat at virtual healthcare showcase. |
| May 07 | Q1 2026 earnings & clinical | Negative | -0.8% | Reported larger net loss and noted LPCN 1154 Phase 3 primary endpoint miss. |
| Apr 02 | Phase 3 topline results | Negative | -77.8% | Topline PPD study failed primary endpoint, with benefit only in post hoc subset. |
| Mar 10 | FY 2025 results & pipeline | Neutral | +2.9% | Full-year results, cash update, and timeline for LPCN 1154 confirmatory study. |
Recent LPCN news, including trial setbacks and earnings updates, has mostly been followed by negative price reactions, even when announcements were neutral or visibility-enhancing.
Over the last few months, LPCN has reported mixed developments. The Phase 3 trial of LPCN 1154 in PPD did not meet its primary endpoint (Apr 2, 2026), triggering a sharp selloff. Subsequent earnings on May 7, 2026 highlighted a wider loss but reiterated cash strength and post hoc clinical signals. Later, data presentations at ASCP and investor appearances in mid‑May were followed by modest declines. Today’s KOL webinar announcement continues the focus on positioning LPCN 1154 despite the earlier trial miss.
Market Pulse Summary
This announcement highlights a virtual KOL event focused on unmet needs in postpartum depression and the clinical profile of LPCN 1154 following a Phase 3 trial that did not meet its primary endpoint. It extends Lipocine’s communication push around post hoc signals and positioning within the PPD landscape. Investors may monitor how expert perspectives, future regulatory feedback, and any updated development plans interact with Lipocine’s broader CNS pipeline and cash resources disclosed in recent filings.
Key Terms
postpartum depression medical
brexanolone medical
phase 3 medical
topline results medical
key opinion leader technical
kol technical
webcast technical
q&a technical
AI-generated analysis. Not financial advice.
Live webinar to take place on Friday, June 12, 2026 at 11:00 AM Eastern Time
The presentations will include a review of the current PPD treatment landscape, persistent gaps in care despite recent therapeutic approvals, and the Phase 3 topline results for LPCN 1154. The KOLs will provide their perspectives on the clinical relevance of the data and how the findings may inform the potential positioning of LPCN 1154 within the PPD and broader depression treatment paradigms.
Lipocine management presenting at the event will include Mahesh V. Patel, Ph.D., President and Chief Executive Officer, and Benjamin Bruno, Ph.D., Vice President of Clinical Development.
A Q&A session will follow the formal presentations.
Event Details
Date: | Friday, June 12, 2026 |
Time: | 11:00 AM Eastern Time |
Format: | Virtual webcast with slides |
Registration: | Advance registration is required. Click here to register. |
Attendees wishing to submit questions in advance of the live Q&A session may do so by emailing questions@lifesciadvisors.com.
A replay of the event will be available on the "events" page of the Lipocine corporate website.
Featured Speakers
Kristina M. Deligiannidis, MD received her medical degree from and completed her psychiatry residency and chief residency in psychopharmacology research at the University of Massachusetts Medical School. Prior to and during medical school she trained in neuroscience research at the National Institutes of Health (NIH). After residency she completed additional research training in behavioral endocrinology and experimental therapeutics at the NIH and in multimodal neuroimaging at the Martinos Center for Biomedical Imaging at Mass General Hospital. Dr. Deligiannidis is the Director of Women's Behavioral Health at Zucker Hillside Hospital, Northwell Health and a Professor of Psychiatry, Molecular Medicine and Obstetrics and Gynecology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. As a reproductive psychiatrist, she has expertise in treating women with mood and anxiety disorders linked to the menstrual cycle, perinatal and perimenopausal periods. Dr. Deligiannidis is a nationally recognized leader in the field of perinatal depression and in novel therapeutics research. Her research program includes a focus in neurosteroids and hormones, and multimodal neuroimaging. Dr. Deligiannidis's research is supported by NIH, foundation, donor and industry funding. For the past decade she served as a principal investigator on the series of clinical trials that led to the FDA approval of two rapid-acting antidepressants for postpartum depression. Dr. Deligiannidis is a current Board of Directors member and President Elect for the Marcé of
Rakesh Jain, MD, MPH is a clinical professor in the Department of Psychiatry at the Texas Tech University Health Sciences Center School of Medicine - Permian Basin in Midland. He is also in private practice in
About LPCN 1154 (BRLIZIO™)
LPCN 1154 is an investigational oral formulation of brexanolone (allopregnanolone), an endogenous neuroactive steroid and potent positive allosteric modulator (PAM) of the GABA₂ receptor. LPCN 1154 is designed to deliver bioequivalent systemic exposure to intravenous brexanolone (ZULRESSO®) via a convenient oral, at-home regimen over 48 hours, without the need for medical monitoring. The drug's mechanism of action, validated through two FDA-approved therapies (ZULRESSO® and ZURZUVAE®), is designed to provide rapid and sustained antidepressant effects in women with PPD.
In a Phase 3 randomized, placebo-controlled trial, LPCN 1154 demonstrated clinically meaningful and statistically significant efficacy across multiple timepoints in a subgroup analysis excluding an identified epidemiologic outlier site. The drug was well tolerated, with
About Postpartum Depression
Postpartum depression is a serious and potentially life-threatening condition affecting approximately 1 in 5 women following childbirth. In
About Lipocine
Lipocine is a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery. Lipocine has drug candidates in development as well as drug candidates for which we are exploring partnerships. Our drug candidates represent enablement of differentiated, patient friendly oral delivery options for favorable benefit to risk profile which target large addressable markets with significant unmet medical needs.
Lipocine's development pipeline includes: LPCN 1154 for the treatment of postpartum depression, LPCN 2201 for treatment of major depressive disorder, LPCN 2101 for the treatment of epilepsy, LPCN 2203 targeted for the management of essential tremor, LPCN 2401 as an aid for improved body composition in obesity management, LPCN 1148 targeted for the management of symptoms associated with liver cirrhosis, and LPCN 1107 our candidate for prevention of preterm birth. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate developed by Lipocine, is approved by the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. For more information, please visit www.lipocine.com.
Forward-Looking Statements
This release contains "forward-looking statements" that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include statements that are not historical facts regarding our development of LPCN 1154 and related efforts with the FDA, the potential uses and benefits of LPCN 1154 on the treatment of PPD, the commercial potential for LPCN 1154, and potential strategic opportunities. Investors are cautioned that all such forward-looking statements involve risks and uncertainties, including, without limitation, the risks that we may not be successful in developing product candidates, we may not have sufficient capital to complete the development processes for our product candidates or we may decide to allocate our available capital to other product candidates, we may not be able to enter into partnerships or other strategic relationships to monetize our assets, safety and efficacy studies, including those relating to LPCN 1154, may not be successful or may not provide results that would support the submission of a NDA, the FDA may not approve any of our products, risks related to our products, expected product benefits not being realized, clinical and regulatory expectations and plans not being realized, new regulatory developments and requirements, risks related to the FDA approval process including the receipt of regulatory approvals and our ability to utilize a streamlined approval pathway for LPCN 1154, the results and timing of clinical trials, patient acceptance of Lipocine's products, the manufacturing and commercialization of Lipocine's products, and other risks detailed in Lipocine's filings with the SEC, including, without limitation, its Form 10-K and other reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at www.sec.gov. Lipocine assumes no obligation to update or revise publicly any forward-looking statements contained in this release, except as required by law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lipocine-inc-to-host-virtual-kol-event-highlighting-unmet-needs-in-postpartum-depression-and-the-clinical-profile-of-lpcn-1154-302790853.html
SOURCE Lipocine Inc.